ArticleScientific reports2026
SIRT3 suppresses renal cancer progression by regulating IDH2 acetylation.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Metabolic reprogramming is a hallmark characteristic of renal cell carcinoma (RCC). SIRT3, a key mitochondrial deacetylase, plays a crucial role in metabolic reprogramming. However, its contribution to RCC development remains unclear. Bioinformatics analysis and immunohistochemistry results showed reduced SIRT3 expression in RCC and its correlation with RCC malignancy. SIRT3 knockdown enhanced cell proliferation and colony formation abilities, suggesting that SIRT3 suppresses RCC progression. Mechanistically, knockdown of SIRT3, increases the level of acetylation of isocitrate dehydrogenase 2 (IDH2) at lysine K413 (IDH2K413ac), which impairs its enzymatic activity, mitochondrial function and redox balance. This effect was reversed by the IDH2 acetylation-mimic mutant K413Q but not by the deacetylation-mimic mutant K413R. Honokiol (HKL), a SIRT3 activator, inhibited RCC cell proliferation and colony formation by increasing SIRT3 levels. Our findings identify a novel mechanism by which SIRT3 suppressed RCC progression. SIRT3 acts as a promising therapeutic target for RCC, with HKL as a potential novel therapeutic agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.